The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema (CHE) who have inadequate response to topical corticosteroids or cannot use them. Regulators granted approval based on data showing local efficacy with minimal systemic exposure and an acceptable safety profile. Delgocitinib’s approval provides a targeted, topical option in a class that has carried systemic black‑box warnings for oral JAK inhibitors; the topical formulation is designed to limit systemic absorption and on‑target adverse events. Clinicians will need to monitor for class‑specific signals, but the approval expands therapeutic options for a difficult‑to‑treat dermatologic condition.